Among the IL-23 p19 inhibitors and also in comparison to IL-17 inhibitors, tildrakizumab seems to have slightly lower efficacy in terms of PASI scores for the treatment of plaque psoriasis in adult patients [52]. Here, IL17A is linked to psoriasis vulgaris.